NCT01285388View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Metabolic SyndromeObesity

Interventions

DRUG

MB12066

MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg

Sponsors

Collaborators (1)

KT&G Corporation

All Listed Sponsors

collaborator

KT&G Corporation

INDUSTRY

lead

Yungjin Pharm. Co., Ltd.

INDUSTRY

NCT01285388 - Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers | Biotech Hunter | Biotech Hunter